News - Eli Lilly, Biotechnology

Filter

Current filters:

Eli LillyBiotechnology

Popular Filters

1 to 25 of 28 results

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

01-06-2014

The 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) began on Friday in Chicago,…

AstraZenecaBiotechnologyCyramzaEisaiEli LillylenvatinibolaparibOncologyRecentinResearch

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Eli Lilly's investigational sNSCLC drug meets Ph III endpoint

14-08-2013

US drug major Eli Lilly's (NYSE: LLY) shares rose nearly 4% to $56.21in pre-market trading when the company…

BiotechnologyBristol-Myers SquibbEli LillynecitumumabOncologyPharmaceuticalResearch

Adocia re-acquires exclusive rights to insulin analog from US drug major

30-07-2013

French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY)…

AdociaBiotechnologyDiabetesEli LillyLicensingPharmaceutical

Pivotal drivers for prescribing metastatic pancreatic cancer drugs: report

09-07-2013

The effect on key efficacy endpoints, primarily the effect of an emerging therapy on overall survival,…

AbraxaneBiotechnologyCelgeneEli LillyEuropeGemzarMarkets & MarketingNorth AmericaOncologyOnconova TherapeuticsPharmaceuticalrigosertib

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats

26-06-2013

An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib

13-06-2013

Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech…

AbbVieAnti-Arthritics/RheumaticsapremilastbaricitinibBiotechnologyCelgeneEli LillyHumiramethotrexatePharmaceuticalResearch

Turkey's NSCLC drug market forecast to expand at 7% a year through 2017

13-06-2013

From 2012 to 2017, the non-small-cell lung cancer (NSCLC) market in Turkey will increase at an annual…

AlimtaBiotechnologyEli LillyEuropeMarkets & MarketingOncologyPharmaceuticalRocheTarceva

Mylan extends deal with Bioton to biosimilar insulins, as Actavis pulls out of JV

14-02-2013

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement…

ActavisBiotechnologyBiotonDiabetesEli LillyGenericsHumalogLantusLicensingMarkets & MarketingMylan LaboratoriesNovo NordiskNovoLogSanofi

Patient trust in drugmakers declining, new report shows

14-01-2013

Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients,…

Abbott LaboratoriesBiotechnologyEli LillyGilead SciencesGlaxoSmithKlineGlobalJanssenLundbeckMarkets & MarketingNovartisNovo NordiskPfizerPharmaceuticalPricingResearchRoche

Nexavar use in Chinese patients nearly doubled in 2012

19-12-2012

Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada

02-11-2012

US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

ASBMR 2012: Anabolics and post-marketing studies

25-10-2012

This year's American Society for Bone and Mineral Research (ASBMR) conference, held in Minneapolis, Minnesota,…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEli LillyMerck & CoodanacatibPharmaceuticalProliaResearchteriparatideUnigene Labs

Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial

11-10-2012

Leading scientists at the USA's Washington University at St Louis have selected the first drugs to be…

BiotechnologyEli LillygantenerumabNeurologicalPharmaceuticalResearchRochesolanezumab

Mixed results with Eli Lilly Alzheimer's drug solanezumab, but investors pleased

09-10-2012

US pharma major Eli Lilly (NYSE: LLY) yesterday reported detailed results from two Phase III studies…

BiotechnologyEli LillyNeurologicalPharmaceuticalResearchsolanezumab

AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance

10-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that, following Bristol-Myers Squibb's…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbDiabetesEli LillyFinancialLicensingPharmaceutical

Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action

02-07-2012

Having rejected a media reported $22 a share offer from the company earlier this year, US biotech firm…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbBydureonByettaDiabetesEli LillyMergers & AcquisitionsPharmaceutical

US NIH debuts collaborative program with Pharma to spur therapeutic development

07-05-2012

The US National Institutes of Health last week unveiled a collaborative program that will match researchers…

AstraZenecaBiotechnologyEli LillyNorth AmericaPfizerPharmaceuticalResearch

1 to 25 of 28 results

Back to top